Stockscreener 앱 받기
3.12
0.32%
-0.010
시장 영업 전:
3.07
-0.05
-1.60%
Rezolute Inc 주식(RZLT)의 최신 뉴스
RZLT.O PE Ratio & Valuation, Is RZLT.O Overvalued - Intellectia AI
Rezolute stock gains after FDA meeting on Ersodetug program update - MSN
Rezolute, Inc. (RZLT) stock price, news, quote and history - Yahoo Finance UK
RZLT Stock Price, Quote & Chart | REZOLUTE INC (NASDAQ:RZLT) - ChartMill
What is HC Wainwright's Estimate for Rezolute Q1 Earnings? - MarketBeat
Rezolute CFO Evans Daron buys $28,500 in RZLT stock By Investing.com - Investing.com India
Rezolute CFO Evans Daron buys $28,500 in RZLT stock - Investing.com
Rezolute (RZLT) CFO adds 10,000 shares in open-market purchase - stocktitan.net
Rezolute Inc (RZLT) Stock Price Quote Today & Current Price Chart - Capital.com
Rezolute Inc (RZLT) Stock Price Quote Today & Current Price Chart | Capital.com Australia - Capital.com
Rezolute: Sell Rating Despite FDA Feedback From Type B Meeting For Ersodetug (NASDAQ:RZLT) - Seeking Alpha
H.C. Wainwright Maintains Rezolute(RZLT.US) With Buy Rating, Maintains Target Price $5 - Moomoo
Will Rezolute Inc outperform during market ralliesTrade Performance Summary & Fast Entry High Yield Stock Tips - baoquankhu1.vn
Rezolute Inc. (RZLT) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
Opaleye Management Inc.'s Rezolute Inc(RZLT) Holding History - GuruFocus
Volume Report: Will Rezolute Inc stock go up in YEAR2026 Dividend Review & Low Risk High Win Rate Picks - baoquankhu1.vn
Vanguard realigns reporting; no beneficial stake in Rezolute (RZLT) - Stock Titan
Analysts Are Bullish on Top Healthcare Stocks: NRX Pharmaceuticals (NRXP), Rezolute (RZLT) - The Globe and Mail
Rezolute (RZLT) Gains Upgrade Following Positive FDA Meeting - GuruFocus
Cantor Fitzgerald Maintains Rezolute(RZLT.US) With Hold Rating - Moomoo
Rezolute Shares Rise After FDA Signals Hope for Treatment Approval - timothysykes.com
Rezolute Shares Rise Following FDA Discussion Regarding Ersodetug Program Progress - Bitget
Rezolute Stock Gains After FDA Meeting on Ersodetug Program Update - The Globe and Mail
Rezolute’s Shares Soar Despite Initial Obstacles in Trial Data - StocksToTrade
Wedbush upgrades Rezolute stock rating on FDA feedback By Investing.com - Investing.com Australia
Citizens reiterates Market Perform on Rezolute stock after FDA update By Investing.com - Investing.com India
RZLT: Wedbush Upgrades Rezolute with Raised Price Target | RZLT Stock News - GuruFocus
Rezolute (NASDAQ:RZLT) Stock Rating Upgraded by Wedbush - marketbeat.com
Cantor Fitzgerald reiterates Neutral on Rezolute stock after FDA meeting By Investing.com - Investing.com Australia
Cantor Fitzgerald reiterates Neutral on Rezolute stock after FDA meeting - Investing.com
Rezolute stock maintained at Buy by H.C. Wainwright after FDA meeting - Investing.com Canada
Wedbush upgrades Rezolute stock rating on FDA feedback - Investing.com
Wedbush Upgrades Rezolute to Outperform From Neutral, Raises Price Target to $5 From $2 - marketscreener.com
Citizens reiterates Market Perform on Rezolute stock after FDA update - Investing.com
FDA Review Puts Rezolute's Genetic Disorder Drug Path In Question - sahmcapital.com
Energy Moves: Is Rezolute Inc a top pick in the sectorMarket Movement Recap & Weekly Consistent Profit Watchlists - baoquankhu1.vn
BTIG reiterates Buy on Rezolute stock, keeps $5 target after FDA update - Investing.com India
BTIG reiterates Buy on Rezolute stock, keeps $5 target after FDA update By Investing.com - Investing.com South Africa
Rezolute Lauds ‘Unusual’ FDA Feedback Supportive of Path Forward for Hypoglycemia Drug - biospace.com
Rezolute Updates on Congenital Hyperinsulinism Program After FDA Meeting; SunRIZE Data Under Review for Potential Advancement 1 - Minichart
Rezolute (RZLT) Shares Surge After Positive FDA Meeting - GuruFocus
Rezolute gains after positive FDA meeting (RZLT:NASDAQ) - Seeking Alpha
Rezolute to submit sunRIZE trial data to FDA for review By Investing.com - Investing.com Canada
Rezolute (RZLT) Discusses sunRIZE Study Results with FDA - GuruFocus
Rezolute Prepares FDA Submission After sunRIZE Trial Review - tipranks.com
Rezolute Says It Had Encouraging FDA Meeting on Congenital Hyperinsulinism Drug Despite Missed Endpoint - marketscreener.com
Rezolute says FDA invited submission of sunRIZE data after Type B meeting; review could inform marketing path - TradingView
Rezolute to submit sunRIZE trial data to FDA for review - Investing.com
Rezolute (RZLT) gets FDA review track for congenital hyperinsulinism trial - Stock Titan
0.49%
1.47%
자본화:
|
볼륨(24시간):